Cellectis to Announce Financial Report for 2024
Cellectis, a pioneering clinical-stage biotechnology company, is set to reveal its financial results for the fourth quarter and entire year of 2024. This announcement will take place on March 13, 2025, coinciding with the closure of U.S. markets. As a prominent player in the biotechnology field, Cellectis leverages its unique gene-editing platform to innovate valuable gene and cell therapies aimed at treating diverse conditions.
Details of the Financial Release
After the financial results announcement, an investor conference call will be conducted on March 14, 2025, at 8:00 AM ET. During this session, the company will disclose critical insights into its performance and provide updates on its business activities. These details are essential for stakeholders, as they allow a better understanding of the company’s strategy and future direction.
The investor call and webcast will cover not only the financial results but also strategic initiatives that reflect Cellectis’ commitment to advancing its pipeline of therapies. With the pressing need for innovative cancer treatments, Cellectis continues to push boundaries in cell and gene therapy development.
Joining the Conference Call
Investors can join the call by dialing into the following numbers:
- Domestic: +1-800-225-9448
- International: +1-203-518-9708
To ensure a smooth experience, please note the conference ID, which is CLLS24, and prepare to engage in a conversation about the exciting developments within Cellectis.
About Cellectis and Its Innovations
Cellectis is headquartered in Paris and operates with a mission to harness its gene-editing expertise through TALEN® technology. By focusing on CAR T immunotherapies for oncology, Cellectis has pioneered the concept of off-the-shelf gene-edited CAR T-cells. This innovation is designed to provide immediate treatment options for cancer patients, highlighting the company's dedication to offering breakthrough solutions that can be readily used.
Cellectis stands out in the biotechnology industry not only for its innovative therapies but also due to its in-house manufacturing capabilities. This allows the company to control the entire value chain for gene therapy, ensuring quality and efficiency from production through to patient delivery.
Company Vision and Global Presence
With aspirations to change the landscape of cancer treatment, Cellectis continues to expand its influence globally. The company maintains operational facilities in strategic locations such as New York and Raleigh, NC, alongside its Paris headquarters. Listed on the Nasdaq Global Market under the ticker CLLS and on Euronext Growth with the ticker ALCLS, Cellectis is poised for future growth as it develops its library of gene therapies across various therapeutic areas.
Cellectis aims to inform and engage both investors and the medical community about its advancements and future initiatives in gene editing and therapies. For more information on the company and its innovations, interested parties can visit Cellectis’s official website or connect through professional networks.
Frequently Asked Questions
When will Cellectis report its 2024 financial results?
Cellectis will report its financial results for the fourth quarter and full year 2024 on March 13, 2025.
How can I participate in the investor conference call?
You can join the investor conference call by dialing in using the provided domestic or international numbers, and using the conference ID CLLS24.
What innovative technologies does Cellectis use?
Cellectis utilizes TALEN® technology in its groundbreaking gene-editing platform to develop CAR T-cell therapies for cancer treatment.
What distinguishes Cellectis in the biotechnology field?
Cellectis differentiates itself through its allogeneic CAR T-cell therapies and its unique ability to manage the entire gene therapy supply chain in-house.
Where is Cellectis located?
Cellectis’ headquarters is located in Paris, France, with additional facilities in New York and Raleigh, NC.
